Sina Gogolin
Overview
Explore the profile of Sina Gogolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryl T, Kuchen E, Bell E, Shao C, Florez A, Monke G, et al.
Cell Syst
. 2017 Aug;
5(3):237-250.e8.
PMID: 28843484
While many tumors initially respond to chemotherapy, regrowth of surviving cells compromises treatment efficacy in the long term. The cell-biological basis of this regrowth is not understood. Here, we characterize...
2.
Harder N, Batra R, Diessl N, Gogolin S, Eils R, Westermann F, et al.
Cytometry A
. 2015 Jan;
87(6):524-40.
PMID: 25630981
Computational approaches for automatic analysis of image-based high-throughput and high-content screens are gaining increased importance to cope with the large amounts of data generated by automated microscopy systems. Typically, automatic...
3.
Gogolin S, Ehemann V, Becker G, Brueckner L, Dreidax D, Bannert S, et al.
Cell Cycle
. 2013 Mar;
12(7):1091-104.
PMID: 23462184
Relapse with drug-resistant disease is the main cause of death in MYCN-amplified neuroblastoma patients. MYCN-amplified neuroblastoma cells in vitro are characterized by a failure to arrest at the G(1)-S checkpoint...
4.
Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner L, Hess E, et al.
Hum Mol Genet
. 2013 Jan;
22(9):1735-45.
PMID: 23343716
The TP53 tumor suppressor pathway is abrogated by TP53 mutations in the majority of human cancers. Increased levels of wild-type TP53 in aggressive neuroblastomas appear paradox but are tolerated by...
5.
Batra R, Harder N, Gogolin S, Diessl N, Soons Z, Jager-Schmidt C, et al.
PLoS One
. 2012 Dec;
7(12):e50988.
PMID: 23251412
Neuroblastoma is the most common extra-cranial solid tumor of early childhood. Standard therapies are not effective in case of poor prognosis and chemotherapy resistance. To improve drug therapy, it is...
6.
Gogolin S, Batra R, Harder N, Ehemann V, Paffhausen T, Diessl N, et al.
Cancer Lett
. 2012 Nov;
331(1):35-45.
PMID: 23186832
High-risk neuroblastomas often harbor structural chromosomal alterations, including amplified MYCN, and usually have a near-di/tetraploid DNA index, but the mechanisms creating tetraploidy remain unclear. Gene-expression analyses revealed that certain MYCN/MYC...
7.
Henrich K, Bauer T, Schulte J, Ehemann V, Deubzer H, Gogolin S, et al.
Cancer Res
. 2011 Mar;
71(8):3142-51.
PMID: 21385898
A distal portion of human chromosome 1p is often deleted in neuroblastomas and other cancers and it is generally assumed that this region harbors one or more tumor suppressor genes....
8.
Muth D, Ghazaryan S, Eckerle I, Beckett E, Pohler C, Batzler J, et al.
Cancer Res
. 2010 Apr;
70(9):3791-802.
PMID: 20424123
The cell cycle regulator, SKP2, is overexpressed in various cancers and plays a key role in p27 degradation, which is involved in tumor cell dedifferentiation. Little is known about the...